|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,630,000,000 |
Market
Cap: |
410.60(B) |
Last
Volume: |
5,973,971 |
Avg
Vol: |
8,200,364 |
52
Week Range: |
$142.06 - $167.7 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
|
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
MAJOR MARKET |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 7.5 |
Insider 3/6 Months : 8.1 |
|
Guru Rank Number : 29 |
Guru Rank Value : 17.2 |
Guru Occurances : 6 |
|
|
|
|
|
|
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
1,000 |
1,000 |
1,000 |
Total Buy Value |
$0 |
$147,220 |
$147,220 |
$147,220 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
20,417 |
20,417 |
26,052 |
141,503 |
Total Sell Value |
$3,226,800 |
$3,226,800 |
$4,156,913 |
$22,809,601 |
Total People Sold |
3 |
3 |
3 |
8 |
Total Sell Transactions |
3 |
3 |
4 |
9 |
End Date |
2025-02-02 |
2024-11-01 |
2024-05-03 |
2023-05-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-03-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
130,852 |
130,852 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-03-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
130,852 |
275,967 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-25 |
4 |
S |
$165.88 |
$1,160,994 |
D/D |
(6,999) |
21,001 |
|
7% |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-25 |
4 |
OE |
$101.87 |
$712,988 |
D/D |
6,999 |
28,000 |
|
- |
|
Wolk Joseph J |
Exec VP, CFO |
|
2025-02-18 |
4 |
D |
$156.15 |
$119,923 |
D/D |
(768) |
5,345 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-02-18 |
4 |
D |
$156.15 |
$250,152 |
D/D |
(1,602) |
395,923 |
|
- |
|
Mulholland Kristen |
EVP, Chief HR Officer |
|
2025-02-18 |
4 |
D |
$156.15 |
$18,738 |
D/D |
(120) |
12,975 |
|
- |
|
Swanson James D. |
EVP, CIO |
|
2025-02-18 |
4 |
D |
$156.15 |
$22,017 |
D/D |
(141) |
16,621 |
|
- |
|
Taubert Jennifer L |
EVP, WWC. Innovative Medicine |
|
2025-02-18 |
4 |
D |
$156.15 |
$101,654 |
D/D |
(651) |
170,459 |
|
- |
|
Broadhurst Vanessa |
EVP, Global Corp Affairs |
|
2025-02-18 |
4 |
D |
$156.15 |
$24,672 |
D/D |
(158) |
21,681 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-18 |
4 |
D |
$156.15 |
$14,678 |
D/D |
(94) |
20,022 |
|
- |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-02-18 |
4 |
D |
$156.15 |
$60,118 |
D/D |
(385) |
15,542 |
|
- |
|
Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
|
2025-02-18 |
4 |
D |
$156.15 |
$31,230 |
D/D |
(200) |
90,837 |
|
- |
|
Schmid Timothy |
EVP, WW Chair, MedTech |
|
2025-02-18 |
4 |
S |
$156.15 |
$62,928 |
D/D |
(403) |
15,098 |
|
0% |
|
Forminard Elizabeth |
Executive VP, General Counsel |
|
2025-02-18 |
4 |
D |
$156.15 |
$47,938 |
D/D |
(307) |
10,014 |
|
- |
|
Wolk Joseph J |
Exec VP, CFO |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,971 |
6,113 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,682 |
397,525 |
|
- |
|
Mulholland Kristen |
EVP, Chief HR Officer |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
419 |
13,095 |
|
- |
|
Swanson James D. |
EVP, CIO |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
492 |
16,762 |
|
- |
|
Taubert Jennifer L |
EVP, WWC. Innovative Medicine |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,594 |
171,110 |
|
- |
|
Broadhurst Vanessa |
EVP, Global Corp Affairs |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
492 |
21,839 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
339 |
20,116 |
|
- |
|
Reed John C |
EVP, Innovative Medicine, R&D |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,350 |
15,927 |
|
- |
|
Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
607 |
91,037 |
|
- |
|
Schmid Timothy |
EVP, WW Chair, MedTech |
|
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,029 |
15,501 |
|
- |
|
641 Records found
|
|
Page 1 of 26 |
|
|